Evobiotics was founded in 2016 with the purpose of discovering and developing novel antimicrobial compounds to treat bacterial and fungal infections in humans. It is currently funded by seed capital from Acidophil to support the research and development activities of its two lead programs, and is actively looking to in-license additional programs.
